These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 10636535)
1. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535 [TBL] [Abstract][Full Text] [Related]
2. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. Cohen M J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM; JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591 [TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F; Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784 [TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L; J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103 [TBL] [Abstract][Full Text] [Related]
7. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Zhao XQ; Théroux P; Snapinn SM; Sax FL Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731 [TBL] [Abstract][Full Text] [Related]
8. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Huynh T; Theroux P; Snapinn S; Wan Y; Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321 [TBL] [Abstract][Full Text] [Related]
9. The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design. Cohen M; Maritz F; Gensini GF; Danchin N; Timerman A; Huber K; Gurfinkel EP; White H; Fox KA; Vittori L; Le-Louer V; Bigonzi F J Thromb Thrombolysis; 2000 Dec; 10(3):241-6. PubMed ID: 11122544 [TBL] [Abstract][Full Text] [Related]
10. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction. Okmen E; Cakmak M; Tartan Z; Cam N Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426 [TBL] [Abstract][Full Text] [Related]
11. Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor. Okmen E; Ozen E; Uyarel H; Sanli A; Tartan Z; Cam N Jpn Heart J; 2003 Nov; 44(6):899-906. PubMed ID: 14711185 [TBL] [Abstract][Full Text] [Related]
12. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818 [TBL] [Abstract][Full Text] [Related]
14. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632 [TBL] [Abstract][Full Text] [Related]
15. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104 [TBL] [Abstract][Full Text] [Related]
16. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846 [TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies? White HD J Invasive Cardiol; 2000 Feb; 12 Suppl A():6A-13A. PubMed ID: 10731290 [TBL] [Abstract][Full Text] [Related]
18. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. Januzzi JL; Hahn SS; Chae CU; Giugliano R; Lewandrowski K; Theroux P; Jang IK Am J Cardiol; 2000 Oct; 86(7):713-7. PubMed ID: 11018188 [TBL] [Abstract][Full Text] [Related]
19. Optimizing outcomes in ST-segment elevation myocardial infarction. Herrmann HC J Am Coll Cardiol; 2003 Oct; 42(8):1357-9. PubMed ID: 14563574 [No Abstract] [Full Text] [Related]
20. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E; N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]